$4.40
+0.00 (+0.00%)
Open$4.41
Previous Close$4.40
Day High$4.57
Day Low$4.39
52W High$20.00
52W Low$3.29
Volume—
Avg Volume22.3K
Market Cap14.10M
P/E Ratio—
EPS$-11.84
SectorBiotechnology
Analyst Ratings
Buy
9 analysts
Price Target
+725.7% upside
Current
$4.40
$4.40
Target
$36.33
$36.33
$21.56
$36.33 avg
$42.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.14M | 4.29M | 4.24M |
| Net Income | -270,468 | -254,054 | -270,426 |
| Profit Margin | -6.5% | -5.9% | -6.4% |
| EBITDA | -483,031 | -431,767 | -494,923 |
| Free Cash Flow | -204,723 | -222,413 | -294,472 |
| Rev Growth | -4.9% | +3.8% | -2.6% |
| Debt/Equity | 0.13 | 0.14 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |